BRPI0600636A - processo para formulações de inibidores da enzima conversora de angiotensina e produto - Google Patents

processo para formulações de inibidores da enzima conversora de angiotensina e produto

Info

Publication number
BRPI0600636A
BRPI0600636A BRPI0600636-1A BRPI0600636A BRPI0600636A BR PI0600636 A BRPI0600636 A BR PI0600636A BR PI0600636 A BRPI0600636 A BR PI0600636A BR PI0600636 A BRPI0600636 A BR PI0600636A
Authority
BR
Brazil
Prior art keywords
product
converting enzyme
angiotensin converting
formulations
enzyme inhibitors
Prior art date
Application number
BRPI0600636-1A
Other languages
English (en)
Inventor
Mariangela De Burgos M Azevedo
Original Assignee
Univ Minas Gerais
Stq Com E Servicos De Tecnolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais, Stq Com E Servicos De Tecnolog filed Critical Univ Minas Gerais
Priority to BRPI0600636-1A priority Critical patent/BRPI0600636A/pt
Priority to PCT/BR2007/000025 priority patent/WO2007087700A1/en
Publication of BRPI0600636A publication Critical patent/BRPI0600636A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

O PROCESSO PARA FORMULAçõES DE INIBIDORES DA ENZIMA CONVERSORA DE ANGIOTENSINA E PRODUTO visa a obtenção de sistema de liberação modificada de um inibidor da Enzima Conversora de Angiotensina - ECA, preferencialmente o Captopril, a partir de sua inclusão molecular nas ciclodextrinas naturais, preferencialmente a <225>-ciclodextrina, e/ou seus alquil e acil derivados, utilizando-se meio aquoso e/ou de solventes orgânicos. O produto, assim obtido, tem diminuída a solubilidade e a instabilidade química do princípio ativo, melhorando os resultados da ação terapêutica.
BRPI0600636-1A 2006-02-03 2006-02-03 processo para formulações de inibidores da enzima conversora de angiotensina e produto BRPI0600636A (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0600636-1A BRPI0600636A (pt) 2006-02-03 2006-02-03 processo para formulações de inibidores da enzima conversora de angiotensina e produto
PCT/BR2007/000025 WO2007087700A1 (en) 2006-02-03 2007-02-05 Process for the preparation of formulations of angiotensin converting enzyme inhibitors and product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0600636-1A BRPI0600636A (pt) 2006-02-03 2006-02-03 processo para formulações de inibidores da enzima conversora de angiotensina e produto

Publications (1)

Publication Number Publication Date
BRPI0600636A true BRPI0600636A (pt) 2007-10-30

Family

ID=37944773

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0600636-1A BRPI0600636A (pt) 2006-02-03 2006-02-03 processo para formulações de inibidores da enzima conversora de angiotensina e produto

Country Status (2)

Country Link
BR (1) BRPI0600636A (pt)
WO (1) WO2007087700A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111529695A (zh) * 2020-04-30 2020-08-14 首都医科大学附属北京康复医院（北京工人疗养院） 一种环糊精可溶性ace2及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
SI8810082A8 (en) * 1988-01-18 1995-12-31 Lek Tovarna Farmacevtskih Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
SI9300470A (en) * 1993-09-10 1995-04-30 Lek Tovarna Farmacevtskih Inclusion complexes of optically active and racemic ibuproxan with cyclodextrin derivates,process for their preparation,pharmaceutical preparations comprising the same and their use
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
WO2007087700A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
EP2058317A4 (en) AMINOOPHOSPHORIC ACID DERTER DERIVATIVE AND THIS ACTIVE MODULATOR OF THE S1P RECEPTOR
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
AR063587A1 (es) Preparcion liquida que comprende pimobendan
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
NO20083640L (no) Antistoff-formulering
WO2008002646A3 (en) Aerosol lotion formulations
SE9903236D0 (sv) Method to obtain microparticles
BRPI0608402B8 (pt) compostos de flavonóide e composições compreendendo os mesmos
MA29857B1 (fr) Derives de triazolopyridine en tant qu&#39;inhibiteurs de lipases et phospholipases
NO20073699L (no) Stabile protaglandin-inneholdende preparater
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CY1112109T1 (el) Σκευασμα αργατροβανης περιεχον ενα οξυ ως διαλυτοποιητη
FR2804286B1 (fr) Utilisation de derives de polyaminoacides comme agents conservateurs, compositions les comprenant et procede de conservation les utilisant
WO2010035122A3 (fr) Complexe constitue d&#39;un polysaccharide et d&#39;une hpb
CY1116189T1 (el) Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina
MA29481B1 (fr) Derives d&#39;azolopyridine-2-one en tant qu&#39;inhibiteurs de lipase et de phospholipase
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
CL2009001183A1 (es) Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico.
ATE458748T1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l&#39;enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
BRPI0600636A (pt) processo para formulações de inibidores da enzima conversora de angiotensina e produto
BRPI0517245A (pt) suspensão farmacêutica e de acetaminofeno isentas de corantes
EP1868613A4 (en) POLYMORPHOS OF 3-O- (3 &#39;, 3&#39;-DIMETHYLSUCCINYL) BETULINIC DI-N-METHYL-D-GLUCAMINE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL